RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.

Conference Call and Webcast Information:

Date: Thursday, November 7, 2024 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Conference ID Code: 60579
Webcast Access: 

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at .

Investor Contact:

Tim McCarthy

LifeSci Advisors



EN
04/11/2024

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignme...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...

January 12, 2026 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at ...

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and ...

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in the adjuvant setting; Studies expected to begin H1 2026 Completed $100M underwritten offering of c...

November 13, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on...

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress. Conference Call and Webcast Information: Date: Thursday, Nove...

November 7, 2025 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Of...

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,315,000 shares of common stock. The share...

November 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch